Engineered ligand-based VEGFR antagonists with increased receptor binding affinity more effectively inhibit angiogenesis.

Autor: Kapur, Shiven1, Silverman, Adam P.1, Ye, Anne Z.1, Papo, Niv1, Jindal, Darren1, Blumenkranz, Mark S.2, Cochran, Jennifer R.1,3,4 jennifer.cochran@stanford.edu
Zdroj: Bioengineering & Translational Medicine. Mar2017, Vol. 2 Issue 1, p81-91. 11p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje